Retraction: Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo (Oncology Reports (2012) 27 (1511-1519) DOI: 10.3892/or.2012.1623);Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1511-1519

  Zhang, Jing ^a   Zhu, Jin Shui ^a   Zhou, Zhou ^a   Chen, Wei Xiong ^a   Chen, Ni Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Ethyl pyruvate; Gastric cancer; Growth; High mobility group box B1; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ETHYLPYRUVATE; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; KI 67 ANTIGEN; PROTEIN KINASE B; PROTEIN P53; PYRUVIC ACID DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT;

EID: 84863245618     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5181     Document Type: Erratum

References (51)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Neugut AI, Hayek M and Howe G: Epidemiology of gastric cancer. Semin Oncol 23: 281-291, 1996. (Pubitemid 26187728)
3. Iiizumi M, Liu W, Pai SK, et al: Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 1786: 87-104, 2008.
4. Kountouras J, Zavos C and Chatzopoulos D: New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 52: 1305-1312, 2005. (Pubitemid 40942236)
5. Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 12: 6469-6479, 2006. (Pubitemid 44799720)
6. Tang D, Kang R, Zeh HJ III, et al: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
7. Taguchi A, Blood DC, del Toro G, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000. (Pubitemid 30337069)
8. Huttunen HJ and Rauvala H: Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 255: 351-366, 2004. (Pubitemid 38315276)
9. Kuniyasu H, Oue N, Wakikawa A, et al: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170, 2002. (Pubitemid 34110897)
10. Jing RR, Cui M, Sun BL, et al: Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer. Genet Test Mol Biomarkers 14: 355-361, 2010.
11. Sasahira T, Akama Y, Fujii K, et al: Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 411-415, 2005. (Pubitemid 40674848)
12. Kostova N, Zlateva S, Ugrinova I, et al: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258, 2010.
13. Ishiguro H, Nakaigawa N, Miyoshi Y, et al: RAGE and its ligand amphoterin are over expressed and associated with prostate cancer development. Prostate 64: 92-100, 2005. (Pubitemid 40734743)
14. Han Z, Wu K, Shen H, et al: Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation. Dig Dis Sci 53: 1801-1810, 2008. (Pubitemid 351748978)
15. Schlegel J, Piontek G, Budde B, et al: The Akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme. Cancer Lett 158: 103-108, 2000. (Pubitemid 30625237)
16. Liu XH, Yu EZ, Li YY, et al: RNA interference targeting Akt promotes apoptosis in hypoxia-exposed human neuroblastoma cells. Brain Res 1070: 24-30, 2006. (Pubitemid 43247740)
17. Nakamura JL, Karlsson A, Arvold ND, et al: PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71: 215-222, 2005. (Pubitemid 40372948)
18. Gupta SK, Rastogi S, Prakash J, et al: Anti-inflflammatory activity of sodium pyruvate-a physiological antioxidant. Indian J Physiol Pharmacol 44: 101-104, 2000. (Pubitemid 30090042)
19. Ulloa L, Ochani M, Yang H, et al: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99: 12351-12356, 2002.
20. Davé SH, Tilstra JS, Matsuoka K, et al: Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 86: 633-643, 2009.
21. Chung KY, Park JJ and Kim YS: The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc 40: 2136-2138, 2008.
22. Liang X, Chavez AR, Schapiro NE, et al: Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 86: 599-607, 2009.
23. Lim SC, Choi JE, Kim CH, et al: Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med 20: 187-192, 2007.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
25. Akaike H, Kono K, Sugai H, et al: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27: 449-457, 2007.
26. Zhang J, Zhang QY, Fu YC, et al: Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. Technol Cancer Res Treat 8: 467-478, 2009.
27. Hanahan D and Weinberg RA: The hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
28. Vazquez A, Bond EE, Levine AJ, et al: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987, 2008.
29. Gnanasekar M, Thirugnanam S and Ramaswamy K: Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34: 425-431, 2009.
30. Zhang P, Liu Y, Wu ZH, et al: Effects of high mobility group box-1 silencing upon the invasion and proliferation in human lung cancer cell L9981 by RNA inhibition. Zhonghua Yi Xue Za Zhi 89: 3156-3159, 2009 (In Chinese).
31. Arumugam T, Ramachandran V and Logsdon CD: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 98: 1806-1818, 2006. (Pubitemid 46017932)
32. Turovskaya O, Foell D, Sinha P, et al: RAGE carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29: 2035-2043, 2008.
33. Hanford LE, Enghild JJ, Valnickova Z, et al: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279: 50019-50024, 2004. (Pubitemid 39577812)
34. Manning BD and Cantley LC: Akt/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007. (Pubitemid 46962095)
35. Nam SY, Lee HS, Jung GA, et al: Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 111: 1105-1113, 2003. (Pubitemid 38091249)
36. Han Z, Hong L, Wu K, et al: Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. J Exp Clin Cancer Res 25: 601-606, 2006. (Pubitemid 46166774)
37. Jiao Y, Wang HC and Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28: 957-967, 2007.
38. Mizutani A, Maeda N, Toku S, et al: Inhibition by ethyl pyruvate of the nuclear translocation of nuclear factor-κB in cultured lung epithelial cells. Pulm Pharmacol Ther 23: 308-315, 2010.
39. Kim SY, Choi JS, Park C, et al: Ethyl pyruvate stabilizes hypoxia-inducible factor 1 alpha via stimulation of the TCA cycle. Cancer Lett 295: 236-241, 2010.
40. Vakkila J and Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641-648, 2004. (Pubitemid 39025049)
41. Kim S, Takahashi H, Lin WW, et al: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009.
42. Czyzewska J, Guzińska-Ustymowicz K, Lebelt A, et al: Evaluation of proliferating markers Ki-67, PCNA in gastric cancers. Rocz Akad Med Bialymst 49 (Suppl 1): 64-66, 2004.
43. Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20: 983-1002, 2006. (Pubitemid 44356460)
44. Vaseva AV and Moll UM: The mitochondrial p53 pathway. Biochim Biophys Acta 1787: 414-420, 2009.
45. Völp K, Brezniceanu ML, Bösser S, et al: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242, 2006. (Pubitemid 43117284)
46. Kang R, Tang D, Schapiro NE, et al: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 17: 666-676, 2010.
47. Fu Y, Zhang Q, Kang C, et al: Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Int J Oncol 35: 583-591, 2009.
48. Park JS, Arcaroli J, Yum HK, et al: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284: C870-C879, 2003. (Pubitemid 36336943)
49. Kawahara K, Hashiguchi T, Kikuchi K, et al: Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells. Int J Mol Med 22: 639-644, 2008.
50. Liu PL, Tsai JR, Hwang JJ, et al: High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 43: 530-538, 2010.
51. Bennett-Guerrero E, Swaminathan M, Grigore AM, et al: A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 23: 324-329, 2009.